These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 23814820

  • 1. Mifepristone as a therapeutic agent in psychiatry.
    Howland RH.
    J Psychosoc Nurs Ment Health Serv; 2013 Jun; 51(6):11-4. PubMed ID: 23814820
    [Abstract] [Full Text] [Related]

  • 2. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
    Gallagher P, Watson S, Elizabeth Dye C, Young AH, Nicol Ferrier I.
    J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
    [Abstract] [Full Text] [Related]

  • 3. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men.
    Mattsson C, Reynolds RM, Simonyte K, Olsson T, Walker BR.
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1347-52. PubMed ID: 19141586
    [Abstract] [Full Text] [Related]

  • 4. Is mifepristone useful in psychotic depression?
    Carroll BJ, Rubin RT.
    Neuropsychopharmacology; 2006 Dec; 31(12):2793-4; author reply 2795-7. PubMed ID: 17109015
    [No Abstract] [Full Text] [Related]

  • 5. Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression.
    Schatzberg AF.
    World J Biol Psychiatry; 2015 Jan; 16(1):2-11. PubMed ID: 24933348
    [Abstract] [Full Text] [Related]

  • 6. Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis.
    Soria V, González-Rodríguez A, Huerta-Ramos E, Usall J, Cobo J, Bioque M, Barbero JD, García-Rizo C, Tost M, Monreal JA, PNECAT Group, Labad J.
    Psychoneuroendocrinology; 2018 Jul; 93():8-19. PubMed ID: 29680774
    [Abstract] [Full Text] [Related]

  • 7. Antiglucocoticoid treatments for depression.
    Young AH.
    Aust N Z J Psychiatry; 2006 May; 40(5):402-5. PubMed ID: 16683965
    [Abstract] [Full Text] [Related]

  • 8. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
    Gross C, Blasey CM, Roe RL, Belanoff JK.
    Obesity (Silver Spring); 2010 Dec; 18(12):2295-300. PubMed ID: 20339369
    [Abstract] [Full Text] [Related]

  • 9. The importance of the hypothalamo-pituitary-adrenal axis as a therapeutic target in anorexia nervosa.
    Bou Khalil R, Souaiby L, Farès N.
    Physiol Behav; 2017 Mar 15; 171():13-20. PubMed ID: 28043861
    [Abstract] [Full Text] [Related]

  • 10. [Stress and psychotic transition: A literature review].
    Chaumette B, Kebir O, Mam Lam Fook C, Bourgin J, Godsil BP, Gaillard R, Jay TM, Krebs MO.
    Encephale; 2016 Aug 15; 42(4):367-73. PubMed ID: 27161263
    [Abstract] [Full Text] [Related]

  • 11. HPA axis alterations in mental disorders: impact on memory and its relevance for therapeutic interventions.
    Wingenfeld K, Wolf OT.
    CNS Neurosci Ther; 2011 Dec 15; 17(6):714-22. PubMed ID: 21143429
    [Abstract] [Full Text] [Related]

  • 12. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.
    Mackin P, Gallagher P, Watson S, Young AH, Ferrier IN.
    Aust N Z J Psychiatry; 2007 Apr 15; 41(4):321-6. PubMed ID: 17464718
    [Abstract] [Full Text] [Related]

  • 13. Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis.
    Lombardo G, Enache D, Gianotti L, Schatzberg AF, Young AH, Pariante CM, Mondelli V.
    Psychoneuroendocrinology; 2019 Dec 15; 110():104420. PubMed ID: 31499391
    [Abstract] [Full Text] [Related]

  • 14. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression.
    Lembke A, Gomez R, Tenakoon L, Keller J, Cohen G, Williams GH, Kraemer FB, Schatzberg AF.
    Psychoneuroendocrinology; 2013 Jan 15; 38(1):115-21. PubMed ID: 22727477
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of psychotropic medications on hypothalamic-pituitary-adrenal regulation.
    Meador-Woodruff JH, Greden JF.
    Neurol Clin; 1988 Feb 15; 6(1):225-34. PubMed ID: 2898096
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical and biological effects of mifepristone treatment for psychotic depression.
    Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF.
    Neuropsychopharmacology; 2006 Mar 15; 31(3):628-36. PubMed ID: 16160710
    [Abstract] [Full Text] [Related]

  • 19. HPA axis in psychotic major depression and schizophrenia spectrum disorders: Cortisol, clinical symptomatology, and cognition.
    Cherian K, Schatzberg AF, Keller J.
    Schizophr Res; 2019 Nov 15; 213():72-79. PubMed ID: 31307859
    [Abstract] [Full Text] [Related]

  • 20. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition.
    Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM, Schatzberg AF.
    Mol Psychiatry; 2017 Apr 15; 22(4):527-536. PubMed ID: 27528460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.